Akers Biosciences Share Discussion Threads

[mcmather] 14/5/2015 10:01

Q1 2014 results:

The first quarter of 2014 has seen the Company begin to put its capital to work through investment in sales and marketing capabilities and product development initiatives", added Dr. Akers

The Company's dedicated technical sales account executives have moved away from a direct selling model for PIFA Heparin/PF4 Rapid Assay products to one that works in tandem with over 300 sales representatives of ABI's US distribution partners, Cardinal Health and Fisher HealthCare. This reorganization and need to dedicate time and resources to building relationships with distributor representatives hampered domestic sales growth in the short term but has set the stage for an enhanced selling effort in 2014.

Revenue for the period ended March 31, 2014 totaled $1,173,919, primarily driven by sales of CHUBE disposable alcohol breathalyzers and PIFA Heparin/PF4 Rapid Assay products.

[rivaldo] 14/5/2015 09:52

Finncap update today as follows, noting that Q1 performance was in line with expectations:

"Akers Biosciences*: Q1 trading update (CORP)

Revenues and loss before income tax for Q1 2015 were in line with management’s expectation at US$510k and US$1.3m, respectively, for the period. The decline in revenues when compared with Q1 2014 (US$1.2m, of which US$766k related to the alcohol breathalyzer business) is due to the company’s alcohol breathalyzer distributer, ChubeWorkx Guernsey Limited, placing no orders for those products in the period. This distributor was positioning the product last year for sales predominantly in France where the opportunity has since been impeded by the French Government’s postponement of the fine that was to be imposed for drivers failing to possess breathalyzers in their vehicles. The decline in revenues from this distributor was therefore anticipated.

What is particularly encouraging, in our opinion, is that US sales of the rapid test to detect a potentially fatal allergy to the blood thinner Heparin, which accounted for almost 50% of last year’s total revenue, were up 17% compared with Q1 2014. This growth does not yet include the impending benefits of either the pricing increase, which took effect in May 2015, or from the expanded US sales team. We reiterate our 310p target price and make no changes to our forecasts.

[norbus] 14/5/2015 09:10

Company had years to deliver; did not amount to much. leopards do not change their spots; Thomas Nicorette was their best chance to get somewhere; Aker Bill blew it as he does

[rivaldo] 14/5/2015 09:03

If anything the amount invested to date tells us that there should be a lot of inherent value in the company which can hopefully be realised.

The market looks at the company as it is, not as it was. The Q2 and Q3 results - along with any further intermediate news flow - will tell us more about the prospects of uplift from the currently low m/cap.

[norbus] 14/5/2015 08:31

AKR looking a basket case; us $85m invested todate with us $8m left; not really suitable as quoted entity;

[rivaldo] 14/5/2015 07:59

Q1 results are in line with expectations, and actually the 17% growth in sales of Heparin is pretty good considering the extra sales force won't affect sales until Q2/Q3.

These are steady as she goes results whilst we wait for bigger things.

Meanwhile AKR has $8.4m net cash against a £15m m/cap, so still plenty of asset backing.

[norbus] 14/5/2015 07:37

I doubt Q1 result atop a history of burst bubbles support the idea of sustainable
business; I think they will be marked down heavily;

[vancoillie] 13/5/2015 16:20

I hope they close higher then $5

[mcmather] 13/5/2015 15:13

Technically:

3rd time lucky re breaking $5 in the US; ie breaking out over there or?

[mcmather] 12/5/2015 09:32

Think this will be well received in the US. Interesting times here what with the ongoing litigation, etc.

[rivaldo] 12/5/2015 07:24

News....in particular:

"The Company is in discussions with a number of strategic partners specializing in the health and wellness industry with regards to the commercialization of OxiChek™, KetoChek™, and BreathScan Lync™



"Akers Biosciences Introduces New Rapid Breath Ketone and Oxidative Stress Tests to the Health and Wellness Industry

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, introduced two new breath tests to the U.S. market from the Company's Akers Wellness division at the World Congress on Anti-Aging Medicine in Hollywood, Florida, USA last week.

etc"

[mcmather] 12/5/2015 00:19

Akers and their management remind me very much of how the glazers are viewed by 90% of united fans.

Dr Walt was still talking fairly recently about plans for the US, Italy, Poland, etc, re the Chube device. Unfortunately, but not at all surprising, all somewhat embarrassing.

[norbus] 11/5/2015 07:46

Akers Biosciences, Inc. Claim Against ChubeWorkx Guernsey Limited ; That is sad since this was looked to for as a sign of life, turnover and profit. Will not be too good to reposess 10% of the company

[mcmather] 10/5/2015 15:30

Metron is a single use device. The software on this one "provides profile management to enable several users to share a device using personal mouthpieces."

This device appears to be more suited to, say, a GP practice. It costs $149.00 or $186.50 if in the EU. I think Metron costs around $5 and probably cheaper for multi-purchases.

Basically just appears to be a similar test for a different target market.

[vancoillie] 08/5/2015 12:13

hxxps://www.ketonix.com/index.php/product/ketonix-2015-blue Is this not the same? This device look even better, or is metron better?

[werewolfie] 06/5/2015 15:48

The disposable breathalyzer market was potentially massive but seemed to slip away into the ether

I will keep an open mind however. As you say, this is far too low key. Wonder what Dr Walt has spent to market this product? As any chimp can sell stuff on the Amazon Marketplace

[mcmather] 06/5/2015 14:34

The target market is potentially massive; "An estimated 45 million Americans diet each year and spend $33 billion annually on weight loss products" with the RNS stating "Achieving a state of ketosis is a goal of many individuals following low carbohydrate diets".

Previous posts on here highlighted the tri-athlete who was interested in the science of ketosis and during his regime tested himself each day if memory serves my right.

Dunno but a standard dieter might test themselves less frequently but even if just a certain percentage of those dieting in the US used this (single use) device it would still have an effect on revenue here.

Just the low key nature of things - eg my mate John is a grafter and sells a bit on ebay & amazon but we'll be on to a winner here I'm sure of it - just provides cause for concern but particularly as dr walt hasn't covered himself in glory these past 13 years decision making wise.

[rivaldo] 06/5/2015 09:07

It's reassuring that the reseller has to achieve contractual milestones to enable their resale agreement to be renewed.

InstaNatural's products on Amazon certainly have terrific ratings achieved from lots of reviews. Hopefully a good augury for later this year...

[werewolfie] 06/5/2015 07:50

Metron has been quiet for a long time, finally some news

[rivaldo] 30/4/2015 14:46

Yep, some keen buying today.

Good start in the USA too, straight up to $5 (EDIT - and back down again!).

[mcmather] 30/4/2015 14:19

???

10:37:09 30-Apr-2015 328.00 2,000 6,560.00 Ordinary trade
10:36:59 30-Apr-2015 328.00 2,500 8,200.00 Ordinary Trade - delayed publication request
10:36:38 30-Apr-2015 328.00 2,500 8,200.00 Ordinary Trade - delayed publication request

Plus trade just gone through at 330p

Plus this from 27 April 2015:

27-Apr-1516:16:47323.0015,000Buy* 300.00330.0048.45k

[werewolfie] 24/4/2015 19:33

Cheers AIM Trader, thats my Friday night sorted!!!!